Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status
Author:
Affiliation:
1. MedImmune Cambridge UK
2. MedImmune Gaithersburg Maryland USA
3. AstraZeneca Macclesfield UK
4. AstraZeneca Cambridge UK
5. AstraZeneca Gaithersburg Maryland USA
Funder
MedImmune
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12633
Reference29 articles.
1. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
2. Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
3. Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
4. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
5. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23
2. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream;Frontiers in Immunology;2024-01-08
3. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13
4. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14
5. Population Pharmacokinetics and Exposure–Response Analysis for the CTLA‐4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study;Clinical Pharmacology & Therapeutics;2023-10-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3